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Abstract: The type I interferon system plays a critical role in limiting the spread of viral 
infection. Viruses induce the production of interferon (IFN), which after binding to the 
IFN- receptor (IFNAR), and triggering of the JAK/STAT signaling cascade, results in 
the induction of interferon-stimulated genes (ISGs). These ISGs function to inhibit viral 
replication and to regulate the host immune response. Among these ISGs, the ubiquitin-like 
molecule, ISG15, is one of the most strongly induced proteins. Similar to ubiquitin, 
through an IFN induced conjugation cascade, ISG15 is covalently linked to a variety of 
cellular proteins, suggesting regulation of different cellular processes. Studies performed 
over the past several years have shown that ISG15 plays a central role in the host’s 
antiviral response against many viruses. Mice lacking ISG15 display increased 
susceptibility to multiple viruses. Furthermore, several viruses have developed immune 
evasion strategies that directly target the ISG15 pathway. Work is now underway to 
determine the mechanism by which ISG15 functions as an antiviral molecule, such that 
therapies targeting this pathway can be developed in the future.  
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1. Introduction—The ISG15 Pathway  
ISG15 was first noted in type I interferon(IFN; IFN-, -β) treated cell lysates in 1984 and was soon 
after identified as having sequence homology to ubiquitin (reviewed in reference [1]) [2,3]. The crystal 
structure of ISG15 revealed that it is composed of two domains, each of which assumes a β-grasp fold 
OPEN ACCESSViruses 2010, 2                  
 
 
2155
similar to the ubiquitin structure [2]. ISG15 is one of the most abundantly-induced transcripts upon 
type I IFN treatment, as well as following TLR ligation and viral infection [3,4]. It is synthesized as  
a 17 kDa precursor protein that is proteolytically processed into its mature 15 kDa form [3]. Following 
stimulation with type I IFN, ISG15 exists in three distinct states- free within the cell, released into the 
extracellular space, or conjugated to target proteins.  
Early after its identification, ISG15 was reported to be found in an extracellular form. Stimulation 
of human monocytes with type I IFN resulted in as much as 50% of the accumulated ISG15 being 
released into the media [5]. Furthermore, the repeated treatment of patients with interferon-βser resulted 
in detectable levels of ISG15 in their sera within 48 hours of treatment [5]. ISG15 doesn’t contain a 
signal sequence; therefore, the mechanism by which it is released remains unknown. Several 
immunomodulatory activities have been attributed to recombinant or extracellular ISG15 including its 
ability to induce NK cell proliferation, augment lymphokine-activated-killer (LAK) activity, stimulate 
the production of IFN-γ, induce DC maturation, and to function as a chemotactic factor for   
neutrophils [6–8]. To date no cell surface receptor has been identified that binds to ISG15; therefore 
the role that its potential cytokine activity plays in vivo is yet to be ascertained.  
Similar to ubiquitin, the mature form of ISG15 contains a C-terminal LRLRGG motif that mediates 
its covalent conjugation to target proteins, termed ISGylation [9,10]. Within two hours after type I IFN 
treatment, free ISG15 is detectable in cell lysates, followed by conjugate formation 12–16 hours   
later [9]. ISGylation utilizes a mechanism similar to ubiquitin, requiring three enzymatic steps   
(Figure 1). The activating E1 enzyme, Ube1L, was initially identified by Robert Krug and colleagues 
and functions only in the ISG15 pathway, forming an ATP-dependent thioester bond with ISG15 [11]. 
The recent generation of an UbE1L knockout mouse has confirmed its role as the ISG15 E1. These 
mice express free ISG15, but do not form ISG15 conjugates following LPS stimulation or during viral 
infection [12]. Following activation, ISG15 is transferred to the active-site cysteine of the conjugating 
E2 enzyme UbcM8/UbcH8 [13,14]. This is followed by the transfer of ISG15 to lysine residues on 
target proteins by the E3 ligases. To date, three E3 ligases have been shown to interact with the ISG15 
pathway and include human HERC5 (Ceb1)/mouse HERC6, HHARI, and Efp [15–20]. ISGylation is 
reversible due to specific removal of ISG15 from conjugated proteins by the deconjugating enzyme 
Ubp43 (USP18) [21,22]. A screen for additional deubiquitinating enzymes that could target ISG15 
conjugates identified USP2, USP5, USP13, and USP14 as potential candidates, whose significance 
remain to be determined in vivo [23]. While in many ways the ISG15 pathway parallels the ubiquitin 
conjugation pathway, there are differences that exist. First, all members of the ISG15 conjugation 
cascade are upregulated by type I IFNs. Second, unlike ubiquitin, in which hundreds of E3s are 
responsible for the individual substrate specificity, in the ISG15 pathway, Herc5 appears to be a 
dominant E3 ligase that coordinates the conjugation of the majority of substrates to ISG15. The 
inhibition of Herc5 expression with siRNA abrogated greater than 90% of the ISG15 conjugate 
formation that was induced [15]. A recent study by Durfee and colleagues has shown the Herc5 
associates with polyribosomes and appears to target newly synthesized proteins, including viral 
proteins, for modification by ISG15, helping to explain the broad substrate specificity of Herc5 [24].  
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Figure 1. ISG15 conjugation cascade. Following exposure to IFN a cell will upregulate 
free intracellular ISG15 (1), conjugate ISG15 to target proteins (2), and release ISG15 into 
the extracellular space (3). Shown in red are the immune evasion strategies utilized by 
viruses to circumvent the ISG15 pathway.  
 
 
Numerous screens have identified nearly 200 candidate ISG15 targets which span a diverse array of 
biological processes, including protein translation, cell cycle regulation, signal transduction, glycolysis, 
cell motility, and immune regulation [25–28]. These targets suggest that ISG15 may be involved in the 
regulation of a variety of host processes. This has been recently reviewed elsewhere [1]. However, it is 
still largely unknown what impact ISG15 modification has on a target protein. Unlike ubiquitination, 
ISGylation does not appear to directly target proteins for proteasome-mediated degradation [29]. 
Chains of ISG15 do not appear to be formed and no interactions between ISG15 and components of 
the proteasome have been identified. Based upon the analysis of a limited number of target proteins, 
ISG15 appears to function by either disrupting the activity of a target protein and/or by altering its 
localization within the cell [30,31]. The mechanism by which this occurs is largely unknown and will 
remain an important focus of future investigations. Interestingly, many of the potential target proteins 
identified include proteins that play an important role in immunity and the host antiviral response, such 
as STAT1, JAK1, RIG-1, ISG56, PKR, and MxA. The recent observation that Herc5 mediates the 
ISGylation of actively translated proteins would make many of these IFN induced proteins important 
targets [24]. It would also provide additional support for ISG15 playing a significant role during viral 
infection. As discussed below, the importance of ISG15 in the host response to viral infection has been 
confirmed in (1) studies evaluating the impact of ISG15 overexpression/knockdown on viral growth  Viruses 2010, 2                  
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in vitro; (2) studies of mice deficient in members of the ISG15 conjugation cascade; and (3) the 
evaluation of viral immune evasion strategies targeting ISG15.  
2. Antiviral Activity of ISG15 
The impact of the ISG15 pathway has been investigated both in vitro and in vivo (Table 1). Studies 
looking at either the overexpression of ISG15 or knockdown of ISG15 using siRNA have implicated it 
in the regulation of influenza, vaccinia, vesicular stomatitis virus (VSV), Sendai, Japanese encephalitis 
virus (JEV), as well as in the release of virus-like particles (VLPs) derived from HIV-1 and avian 
sarcoma leukosis virus (ASLV) [24,32–39]. There has also been a recent report that ISG15 functions 
as a proviral molecule, augmenting hepatitis C virus (HCV) replication, although the mechanism is yet 
to be determined [40]. Studies utilizing siRNA that target ISG15 have also shown either increased viral 
growth (vaccinia, Sendai, NDV) or an ability to partially rescue type I IFN induced inhibition of 
growth (influenza A, Ebola VLPs, HIV-1) [32,34,38]. In most cases these effects have been modest, 
with changes in viral growth ranging between 5-20 fold. The mechanism by which ISG15 is regulating 
viral growth is unknown for the majority of these pathogens. In most overexpression studies, ISG15 
and members of its conjugation cascade have been co-expressed, suggesting that the conjugation of 
ISG15 to target proteins is required for these antiviral effects. An exception is the studies of Ebola 
virus VLP release, in which the overexpression of only ISG15 inhibited VLP budding [32,39]. Despite 
these observations with either overexpression or knockdown strategies, no differences in viral growth 
of influenza A, herpes simplex virus (HSV-1), Sindbis, VSV or wild type vaccinia virus have been 
reported in cells derived from either ISG15-/- or UbE1L-/- mice [12,41,42]. Furthermore, it is 
unknown if these in vitro effects will translate into differences in vivo. For example, while defects in 
VSV budding were noted in an ISG15 overexpression study, to date, no phenotype has been observed 
or reported in mice infected with VSV that lack either ISG15 or UbE1L [12,32,42]. Future studies are 
needed to confirm these phenotypes in vivo. 
The strongest evidence for ISG15 functioning as an antiviral molecule has come from the analysis 
of mice in which ISG15 or members of the conjugation cascade have been deleted. The first 
genetically deficient mouse to be generated in the pathway was the deconjugating enzyme, Ubp43. 
These mice died around 4 weeks of age from hydrocephalus [43]. Characterization of these mice found 
them to have increased levels of ISG15 conjugates, increased IFN signal transduction as noted by 
prolonged STAT-1 phosphorylation, and increased production of ISGs [44,45]. They were also 
resistant to both viral and bacterial infections, suggesting that the dysregulation of ISG15 conjugation 
was leading to this phenotype [45]. This conclusion was challenged when the initial characterization of 
ISG15-/- mice revealed no defect in their development, intact interferon signaling, and normal 
resistance to VSV and lymphocytic choriomeningitis virus (LCMV) infection [42]. In addition, the 
phenotypes observed in the Ubp43-/- mice were not abrogated upon the generation of mice lacking 
both Ubp43 and ISG15, indicating that the phenotype of the Ubp43-/- mouse was independent of 
ISG15 [46]. Subsequent studies have determined that Ubp43, in addition to its role as an ISG15 
deconjugating enzyme, also functions as a negative regulator of type I IFN receptor signaling [47].  
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Table 1. Studies evaluating the antiviral activity of ISG15. 
Virus  Method  Cell Type  Viral Growth  Reference 
Influenza A 
(A/WNS/33) 
ISG15-/-  MEFs  No difference  [41] 
Influenza A 
(A/Udorn/72) 
siRNA (ISG15 + 
UbE1L) 
Calu3 
Rescued IFN induced inhibition of 
growth by 10–20 fold at 4 hrs. 
 
[34] 
Influenza A 
(A/PR8/34) 
siRNA (ISG15) or 
siRNA (Herc5) 
A549 
4 fold increase in viral 
infectivity 
[51] 
Vaccinia WR  ISG15-/-  MEFs No  difference  [33] 
  ISG15 overexpression  ISG15-/- MEFs  5 fold decrease in viral titers  [33] 
  siRNA (ISG15)  WT MEFs  15 fold increase in viral titers  [33] 
Vaccinia virus (ΔE3L)  ISG15-/-  ISG15-/- MEFs  25 fold increase in viral titers  [33] 
 ISG15  overexpression  ISG15-/-  MEFs  25 fold decrease in viral titers  [33] 
  siRNA (ISG15)  WT MEFs  15 fold increase in viral titers  [33] 
VSV (Indiana)  ISG15-/-  ISG15-/- MEFs  No difference  [42] 
VSV  UbE1L-/-  
UbE1L-/- 
MEFs 
No difference in VSV  
protection assay 
[12] 
VSV-(Indiana)  ISG15 overexpression  293 T cells  10 fold decrease in viral titers  [32] 
VSV-PY>A4 mutant  ISG15 overexpression  293 T cells  No effect  [32] 
Ebola VP40 VLPs  ISG15 overexpression  293 T cells  Inhibited Ebola VP40 VLP release  [32] 
  siRNA (ISG15)  293 T cells 
Rescued IFN induced inhibition of 
Ebola VP40 VLP budding 
[32] 
Ebola VP40 VLPs 
(Zaire strain) 
ISG15 overexpression  293 T cells  Inhibited Ebola VP40 VLP release  [39] 
  ISG15-/-  ISG15-/- MLFs 
2 fold increase in VP40 release 
from cells expressing HA-VP40 
 
[39] 
HIV-1 provirus (NL43)  ISG15 overexpression  293 T cells  Inhibited release of HIV  [38] 
  siRNA (ISG15)  293T cells 
Rescued IFN mediated inhibition 
of HIV release 
[38] 
ASLV Gag VLP  ISG15 overexpression  293/E cells  Inhibited ASLV VLP release  [37] 
HIV Gag VLP  ISG15 overexpression  293/E cells  Inhibited HIV VLP release  [37] 
SeV  siRNA (ISG15 or Herc5)  HEK293  5 fold increase in viral titers  [36] 
NDV-GFP  siRNA (Herc5)  HEK293  10 fold increase in GFP+ cells  [36] 
JEV (strain T1P1)  ISG15 overexpression  Te-671   10-50 fold decrease in viral titers  [35] 
HPV pseudovirus  ISG15 overexpression  293 T cells 
Decreased infectivity of 
pseudovirus generated in ISG15 
expressing cells  
[24] 
HCV replicon 
(genotype 1b replicon 
I377/NS3-3) 
siRNA (ISG15) 
MH1 cells  
or con1 cells 
Decreased HCV replication as 
assessed by RT-PCR. 
 
[40] 
HCV (J6/JFH-1)  siRNA (ISG15)  Huh 7.5 cells  Decreased HCV replication   [40] 
  ISG15 overexpression  Huh 7.5 cells  Increase in replication   [40] 
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Table 1. Cont. 
Virus System  Lethality  Viral  titers  Reference 
Influenza A virus (WSN/33/A)  ISG15-/- mice  Increased  N.T.  [41] 
Influenza B virus (B/Lee/40)  ISG15-/- mice  Increased  Increased 3-4 logs   [41] 
  UbE1L-/- mice  Increased   Increased 3-4 logs  [50] 
Influenza B virus (B/Yamagata/88)  ISG15-/- mice  Increased   Increased 3-4 logs  [50] 
  UbE1L-/- mice  Increased  Increased 3-4 logs  [50] 
Influenza B virus (B/Yamagata/73)  ISG15-/- mice  N.T.  Increased 2-3 logs  [50] 
  UbE1L-/- mice  N.T.  Increased 2-3 logs  [50] 
Sindbis virus (dsTE12Q)  ISG15-/- mice  Increased  N.T.  [41,48] 
dsTE12Q-ISG15 LRLRGG  ISG15-/- mice  Protected from lethality    [48] 
dsTE12Q-ISG15 LRLRAA  ISG15-/- mice  No protection    [48] 
dsTE12Q-ISG15 LALRGG  ISG15-/- mice  No protection    [49] 
Sindbis virus (dsTE12Q)  UbE1L-/- mice  Increased  N.T.  [49] 
HSV-1 (strain 17)  ISG15-/- mice  Increased  N.T.  [41] 
γHV68  ISG15-/- mice  No difference  Increased 10 fold  [41] 
Vaccinia virus (WR)  ISG15-/- mice  No difference  Increased 3 fold  [33] 
Vaccinia virus (VVΔE3L) ISG15-/-  mice  Increased None  detected  [33] 
Vaccinia virus (VVE3LΔ26C)  ISG15-/- mice  Increased  No difference  [33] 
VSV (Indiana strain)  ISG15-/- mice  No difference  N.T.  [42] 
LCMV (WE strain)  ISG15-/- mice    No difference  [42] 
LCMV (Armstrong strain)  UbE1L-/- mice  No difference  N.T.  [12] 
HBV  
(pSP65-ayw1.3 genome) 
UbE1L-/- mice 
Injection of naked 
plasmid DNA 
N.T. 
No difference in 
viral replication 
[61] 
Vesicular stomatitis virus (VSV), Human immunodeficiency virus-1 (HIV-1), Sendai virus (SeV), 
Newcastle disease virus- green fluorescent protein (NDV-GFP), Avian sarocoma leukosis virus 
(ASLV), Japanese encephalitis virus (JEV), human papillomavirus (HPV), hepatitis C virus (HCV), 
gammaherpes virus68 (γHV68), herpes simplex virus-1 (HSV-1), lymphocytic choriomeningitis 
virus (LCMV) hepatitis B virus (HBV). Lethality and viral titers were compared to responses in 
WT mice; N.T. = not tested/reported.  
 
Confirmation that ISG15 functions as an antiviral molecule has come from the careful analysis of 
ISG15
-/- mice. ISG15
-/- mice, as compared to wild type mice, were more susceptible to infection with 
Sindbis virus, influenza A and B virus, HSV-1, and murine gammaherpesvirus 68 [41]. While both 
free ISG15 and ISG15 conjugates were detected during viral infection, ISGylation was shown to be 
required for ISG15-dependent resistance to Sindbis and influenza virus in vivo. The increased lethality 
seen in ISG15-/- mice infected with Sindbis virus could be rescued by a double subgenomic Sindbis 
virus expressing wild type ISG15, but was not rescued by viruses containing mutations in the terminal 
LRLRGG motif, which abrogated conjugation [41,48,49]. In addition, mice lacking the ISG15 E1 
enzyme, UbE1L, which still express free ISG15, but fail to form ISG15 conjugates, were also 
susceptible to both Sindbis virus and influenza virus infection [48,50]. Studies of vaccinia virus found 
that ISG15-/- mice displayed no differences in lethality and had a minimal increase in viral loads 
following infection with wild type virus [33]. The E3 protein was identified as an ISG15 antagonist, Viruses 2010, 2                  
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which inhibited ISG15 conjugation [33]. Infection of ISG15-/- mice with a mutant virus lacking this 
ISG15 antagonist did result in increased lethality as compared to WT mice, providing another model in 
which ISG15 played a role. Therefore in these viral systems the antiviral action of ISG15 is mediated 
through its conjugation to target proteins. Further investigation is now needed to determine the viral 
and host proteins that are targeted during infection, and to understand the mechanism by which this 
modification impacts upon the virus. 
3. Mechanism(s) of Antiviral Activity 
The mechanism by which ISG15 is functioning as an antiviral molecule is unknown, and likely 
differs between viruses. Recent studies have provided some insight into how ISG15 regulates the host 
antiviral response to some viruses.  
3.1. Disruption of Viral Budding 
A series of studies looking at viruses that utilize the host ubiquitin machinery for viral egress have 
implicated ISG15 as an important regulator of this pathway. Both retroviruses and filoviruses utilize 
the endosomal sorting complex required for transport (ESCRT I-III) pathway for viral egress. 
Okumura et al. were the first to demonstrate that the over-expression of ISG15 mimicked the ability of 
type I IFN to block the release of HIV particles from cells. Through the utilization of siRNA, they 
found that this inhibition was due to the activity of ISG15 [38]. ISG15 overexpression inhibited the 
ubiquitination of both HIV Gag and host Tsg101. This disrupted the interaction between these 
proteins, which was known to be critical for efficient viral budding [38]. The authors failed to detect 
ISGylation of either HIV Gag or Tsg101 directly. They proposed that this loss of ubiquitination may 
lead to a less stable budding complex, and therefore decreased budding.  
This observation was followed by two independent studies demonstrating that ISG15 also inhibited 
Ebola virus VP40 VLP release [32,39]. Budding in this system requires the interaction of the VP40 
late domain with members of the host ESCRT pathway (i.e. Tsg101). Monoubiquitination of VP40, 
mediated by the Nedd4 E3 ligase, is thought to be required for efficient release. In studies by both 
Okumura et al. and Malakhova et al. the overexpression of ISG15, independent of the conjugation 
system, inhibited Ebola virus VP40 VLP release. Mechanistically, they found that ISG15 interacted 
with Nedd4 and abrogated the transfer of ubiquitin from the E2 enzyme to the active site of Nedd4 
[32,39]. This prevented Nedd4-mediated ubiquitination of target proteins including Ebola virus VP40. 
They extended these studies to VSV, a rhabdovirus which contains a similar L-domain and also 
interacts with Nedd4 ligase for efficient budding [32]. These two studies identified a mechanism by 
which ISG15 regulated viral budding, and for the first time, implicated unconjugated ISG15 as an 
antiviral molecule. 
An additional mechanism by which ISG15 targets retroviral release from cells late in the budding 
process has recently been identified. The release of (ASLV) VLPs, similar to HIV-1, was inhibited by 
the overexpression of ISG15 [37]. The expression of ISG15 inhibited ASLV Gag ubiquitination, 
supporting the earlier findings. However, the authors were able to reconstitute Nedd4 independent 
budding by covalently linking either ASLV or HIV-1 Gag proteins to the ESCRT-III protein, CHMP6, 
allowing ASLV and HIV-1 Gag to enter their respective budding pathways at a late step in the budding Viruses 2010, 2                  
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process [37]. These constructs were still inhibited by ISG15, suggesting a second mechanism for 
ISG15 mediated inhibition of viral release. The ectopic expression of ISG15 blocked the association of 
HIV-1 Gag and ASLV Gag with Vps4, by inhibiting the interaction between Vps4 and its co-activator, 
LIP5 [37]. This prevented the formation of the oligomeric enzyme needed to disassemble the ESCRT 
complex and facilitate multiple rounds of budding. The ESCRT-III protein, CHMP5, was noted to be 
modified by ISG15, and depletion of CHMP5 by siRNA made the budding of ASLV and HIV-1 VLPs 
resistant to ISG15 inhibition [37].  
Together, these studies provide the first insight into one mechanism by which ISG15 may regulate 
viral infection, by targeting multiple stages of budding for viruses that utilize ubiquitin machinery and 
ESCRT pathway. In most cases, these studies were performed using overexpression systems. Whether 
these interaction/modifications also take place, and are significant, during viral infection in cells or in 
animal models remains to be determined.  
3.2. Modification of Viral Proteins 
Host proteins have clearly been identified as targets of ISGylation, although as discussed above, the 
impact of this modification is still largely debated. A persistent question had been whether viral 
proteins are also targeted for ISG15 modification. Recently two groups have demonstrated the 
modification of the influenza A viral protein, NS1, which functions as an IFN antagonist, during viral 
infection [51,52]. In the study by Zhao et al., the authors determined that during viral infection the 
dominant lysine that was modified by ISG15 was at position 41 in the RNA-binding domain of NS1, 
and that ISGylation at this site disrupted its association with importin-, a protein required for the 
nuclear import of NS1 [52]. The generation of a recombinant virus in which this lysine residue was 
mutated (K41R), resulted in greatly reduced ISGylation of NS1 during viral infection, and demonstrated 
that the ISGylation of NS1 inhibited replication of influenza in IFN-β-treated cells [52]. In a second study 
by Tang, et al. the authors identified seven lysines (K20/41/108/110/126/217/219) in the PR8 NS1A as 
potential ISGylation sites, with K126 and K217 found to be critical in vivo [51]. The generation of mutant 
viruses carrying the K  R mutations at either of these lysine residues resulted in augmented viral growth 
in cultured cells and increased virulence in vivo [51]. These studies provided the first evidence that viral 
proteins are also targeted for ISGylation and that this modification impacts virulence. Future 
experiments are needed to determine whether NS1 is the only influenza viral protein modified during 
influenza virus infection. Finally, a recent study by Durfee et al. found that the E3 ligase, Herc5, 
associated with polyribosomes, and therefore targeted newly synthesized proteins for modification by 
ISG15 [24]. The authors proposed that viral proteins would be a primary target of ISGylation, and they 
went on to demonstrate that the HPV16 L protein was ISGylated in transfection experiments [24]. 
When an HPV pseudovirus system was utilized to determine if ISGylation impacted infectivity, the 
authors found that HPV16 pseudovirus generated in cells cotransfected with ISG15, E1, E2, and E3 
resulted in decreased infectivity of the virus [24]. It remains to be seen if modification of the L protein 
occurs during viral infection. Taken together, these results support viral proteins as targets for ISG15. 
Additional work is needed to determine if this modification accounts for the entire phenotype seen in 
mice lacking ISG15, or if host protein modification also contributes to the antiviral action of ISG15.  
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3.3. Modification of Host Proteins 
Many of the target proteins identified by proteomic screens include proteins that play an important 
role in immunity, such as STAT1, JAK1, RIG-1, ISG56, PKR, and MxA [25–27]. Modification of 
these proteins may contribute to antiviral activity against specific viruses, although at this point in time 
their contribution to the antiviral state is unclear, due, in part, to the unknown fate of the vast majority 
of ISGylated target proteins. Recently, the mechanism by which ISG15 alters the function of several 
substrates has been identified. It appears that ISG15 can directly impact the function of the modified 
protein or it indirectly impacts its function by disrupting ubiquitination. For example, ISG15 
negatively regulates the scaffold protein filamin B [30]. Unmodified filamin B facilitates type I   
IFN-induced apoptosis by recruiting RAC1, MEKK1, MKK4, and JNK1. ISGylation of filamin B, 
however, releases RAC1, MEKK1, and MKK4 from the scaffold, preventing IFN-β-dependent JNK 
activation and apoptosis [30]. It has been suggested that this mechanism may protect uninfected 
bystander cells from IFN-mediated apoptosis, but this hypothesis awaits further experimentation. In 
contrast, ISG15 conjugation positively regulates the transcription factor IRF3 that promotes type I IFN 
induction [36,53]. ISGylation of IRF3 abolishes its binding to Pin1, a protein that promotes IRF3 
ubiquitination and subsequent degradation [36]. ISG15-dependent inhibition of the IRF3-Pin1 
interaction correlates with decreased IRF3 degradation and increased IFN-β induction [36]. ISG15 
modification of several ubiquitin E2s (Ubc13, UbcH6, and UbcH8) has been shown to disrupt the 
ability of these E2s to form thioester bonds with ubiquitin, and therefore disrupts the ubiquitination of 
downstream targets [31,54]. The contributions of these and other ISG15 modified host proteins to the 
antiviral activity of ISG15 are still under investigation.  
4. Immune Evasion Strategies Targeting ISG15 
Host pathways that play a significant role in the antiviral response are often targeted by viruses. 
Viral immune evasion strategies have been identified that target the ISG15 pathway (Figure 1), 
providing further support for the importance of this pathway in the host anti-viral response. To date, all 
of the evasion strategies have targeted ISG15 conjugation by either inhibiting the formation of 
conjugates or by disrupting the conjugates once formed. 
The first identified immune evasion strategy targeting the ISG15 pathway was described by Robert 
Krug and colleagues while studying interacting partners for the influenza viral protein, NS1 [11]. They 
determined that while the infection of cells at a high MOI with various influenza B viral strains 
upregulated free ISG15, no ISG15 conjugates were detected. The mechanism for this inhibition was 
mediated by the NS1/B gene, which non-covalently bound to ISG15 and inhibited the ability of the 
ISG15 E1, UbE1L, from interacting with and subsequently activating ISG15, thereby inhibiting 
conjugate formation [11]. While the NS1 proteins of both influenza A and B viruses are antagonists  
of IFN, only B/NS1, and not A/NS1 retained the ability to bind to ISG15 and inhibit conjugate 
formation [11]. Despite this evasion strategy, the ISG15-/- and UbE1L-/- mice are highly susceptible 
to influenza B virus infection [41,50]. This appears to be due largely to the species specificity of the 
B/NS1-ISG15 interaction, with B/NS1 binding only to human and non-human primate ISG15, but not Viruses 2010, 2                  
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to murine or canine ISG15 [20,55]. This may provide important insight into the more restricted host 
range of influenza B viruses as compared to influenza A viruses.  
In addition to influenza B virus, vaccinia virus has also been shown to encode a viral protein that 
antagonizes ISG15. In this case the E3 protein, which is known to antagonize the host IFN response by 
several mechanisms (inhibiting PKR, RNaseL and blocking IRF3 activation), was also shown to bind 
to ISG15 through its C-terminal domain [33]. Once again this protein appears to inhibit ISG15 
conjugate formation, although the precise mechanism remains to be determined. In this model, ISG15-/- 
mice display almost no differences from WT mice following infection with wild type vaccinia virus. 
However, deletion of the E3 protein from the virus resulted in increased virulence in the ISG15-/- 
mice, demonstrating its role in the host response, and the efficacy of the immune evasion strategy 
mounted by vaccinia virus [33]. 
In contrast to the first two examples, the remaining strategies have taken advantage of the protease 
activity of different viruses to hydrolyze both ubiquitin and ISG15 from target proteins. The first 
strategy identified is employed by several viruses with ovarian tumor domain (OTU)-containing 
proteases [56]. The OTU domain family has recently been identified as deubiquitinating (DUB) 
enzymes comprised of a group of cysteine proteases which participate in substrate-specific 
deubiquitination. The L proteins from both Crimean Congo hemorrhagic fever virus (CCHFV) and 
Dugbe virus (DUGV), as well as the nsP2 proteins from the arteriviruses, equine arteritis virus (EAV) 
and porcine respiratory and reproductive syndrome virus (PRRSV), contain OTU domains. Unlike 
their mammalian counterparts (Cezanne and A20) which only had deubiquitinating activity against 
specific substrates, these viral proteins were found to globally deconjugate both ubiqitin and ISG15 
chains, via their cysteine protease activity, but had no activity against SUMO-2 or SUMO-3   
conjugates [56]. Expression of these viral OTU domains through either the generation of a transgenic 
mouse expressing the CCHFV L protein or by overexpressing this protein directly from a recombinant 
Sindbis virus was able to inhibit the antiviral activity of ISG15 [56]. In addition, these viral OTU 
proteases were able to inhibit NF-κB dependent signaling [56]. Finally, in addition to OTU domain 
containing proteases, recent work looking at the papain-like proteases of both the SARS coronavirus 
(SARS-CoV PLpro) and the human coronavirus NL63 (HCoV-NL63 PLP2) proteins has found that 
both can deubiquitinate and deISGylate target proteins [57,58]. The significance of this activity during 
viral infection is still under investigation. In both cases, this viral immune evasion strategy allows 
these viruses to evade both the IFN and TNFα signaling pathways, both of which play a critical role in 
the host response to viral infection. 
5. Conclusion 
Significant progress has been made in identifying the components of the ISG15 conjugation 
cascade, understanding how these proteins are induced during viral infection, and identifying potential 
targets for ISGylation. While ISG15 may regulate a variety of cellular processes, it appears to play a 
critical role in the host response to viral infection. This is supported by studies in ISG15-/- and 
UbE1L-/- mice, and also in the identification of viral immune evasion strategies that target the ISG15 
pathway. Several viral systems appear to be regulated by ISG15, based upon both in vitro and in vivo 
studies. Recent efforts have begun to dissect the mechanism by which ISG15 is regulating these Viruses 2010, 2                  
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responses. However, despite this progress many questions still remain and will be the focus of future 
investigations. First, for many of the viral systems, observations made from either overexpression 
studies or knockdown studies will need to be confirmed in vivo. Second, additional mechanistic studies 
will be necessary to understand how ISG15 is regulating such a diverse group of viruses. Only after 
this information is in hand will we be able to develop therapeutics that target this pathway. Third, 
while viral proteins can be ISGylated, at least during influenza virus infection, it remains unclear if the 
antiviral effects of ISG15 are due solely to modification of viral proteins, or if the modification of host 
proteins also contributes to this antiviral effect. Fourth, the report by Durfee et al. suggests that only 
actively translated proteins will be targeted for ISGylation, at least by Herc5 [24]. These would include 
the many genes that are induced by type I IFN, and will be expressed in cells which are not virally 
infected. The impact of ISGylation on these proteins and what is their fate remains unanswered. Fifth, 
to date the antiviral activities of ISG15 and the identified viral immune evasion strategies have targeted 
ISG15 conjugation. However, studies with the Ebola VLPs suggest that free, unconjugated ISG15 may 
mediate its antiviral effects [32,39]. Unanchored ubiquitin chains have recently been shown to modify 
both the NF-kB and RIG-I signaling pathways [59,60]. Therefore, evaluating the potential activity of 
unconjugated ISG15, both within the cell, and that which is released from the cell, will be of interest. 
Finally, IFNs have pleotropic effects on the immune response. Determining whether ISG15 plays a 
role in these responses could have important consequences for the development of future therapeutic 
and vaccine strategies. 
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